Tislelizumab Benefit in HCC Undimmed by Prior Therapies Tislelizumab Benefit in HCC Undimmed by Prior Therapies

Patients with advanced hepatocellular carcinoma (HCC) can achieve durable responses, and overall survival is"encouraging" with the novel immunotherapy, even after multiple prior therapies.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news